Read this topic

Think of the liver as having two separate workshops for breaking down benzodiazepines: an oxidation workshop (fragile, shuts down early in liver disease) and a conjugation workshop (glucuronidation, sturdier, keeps working even when the liver is quite damaged). Drugs that only need the conjugation workshop — lorazepam, oxazepam, temazepam — get processed reliably; drugs that need the oxidation workshop first pile up unprocessed.

• Most benzodiazepines are inactivated by hepatic oxidation (CYP-mediated phase I metabolism), often producing active intermediate metabolites before final conjugation.
• Oxidative (phase I) capacityA person's ability to understand, weigh up, and use relevant information to make a specific decision.Read more → falls disproportionately in cirrhosis and hepatic impairment, so oxidised benzodiazepines and their active metabolitesA breakdown product of a drug that is itself still able to produce an effect in the body.Read more → accumulate.
• Lorazepam, oxazepam and temazepam ('LOT') skip hepatic oxidation entirely and are conjugated directly by glucuronidation (phase II), a pathway that is comparatively preserved in liver disease.
• Glucuronidation produces inactive, water-soluble glucuronide conjugates that are renally excreted, giving more predictable clearanceThe rate at which the body removes a drug from the blood.Read more → when the liver is failing.
• This is why the 'LOT' rule (Lorazepam, Oxazepam, Temazepam) is taught as the safe benzodiazepine set in hepatic impairment, including alcohol withdrawal regimens in cirrhotic patients.
• Diazepam and chlordiazepoxide, the usual first-line detox agents, are avoided in significant hepatic impairment because their oxidative clearanceThe rate at which the body removes a drug from the blood.Read more → and active metabolitesA breakdown product of a drug that is itself still able to produce an effect in the body.Read more → can cause dangerous over-sedation and precipitate hepatic encephalopathyA general term for brain dysfunction, often causing confusion, that has a physical cause.Read more →.

• A 58-year-old man with decompensated alcoholic liver cirrhosis (Child-Pugh C) is agitated and requires a benzodiazepine for symptomatic alcohol withdrawal.
• A patient with cirrhosis needs a benzodiazepine to cover an alcohol detoxification regimen.
• A hepatologist asks which pathway of drug metabolism is relatively spared in cirrhosis compared with oxidative (phase I) hepatic metabolism.

• Diazepam and chlordiazepoxide — require hepatic oxidation and form active metabolitesA breakdown product of a drug that is itself still able to produce an effect in the body.Read more →; accumulate in hepatic impairment, unlike the LOT drugs.
• Clonazepam and nitrazepam — also oxidatively metabolised with long half-lives; not preferred when hepatic oxidative capacityA person's ability to understand, weigh up, and use relevant information to make a specific decision.Read more → is reduced.
• Lorazepam, oxazepam, temazepam — glucuronidated directly, no active metabolitesA breakdown product of a drug that is itself still able to produce an effect in the body.Read more →, preserved clearanceThe rate at which the body removes a drug from the blood.Read more → in liver disease.
• Renal impairment vs hepatic impairment — glucuronide conjugates are renally excreted, so LOT drugs need caution (not preference) in significant renal failure, the mirror-image scenario.
• Within the LOT group itself, lorazepam — not oxazepam or temazepam — is the one specifically preferred for alcohol-withdrawal treatment: it is available in parenteral (IM/IV) form for severe withdrawal or delirium tremens, or when oral intake is unreliable, giving a faster, more titratable effect, whereas oxazepam and temazepam are oral-only.

• Assuming all benzodiazepines are equally hazardous in liver disease — the metabolic pathway, not the drug class as a whole, determines safety.
• Choosing diazepam for alcohol withdrawal reflexively (it is first-line in preserved hepatic function) without checking for cirrhosis or deranged LFTsLiver function tests, a blood test that checks how well the liver is working.Read more → in the stem.
• Forgetting that glucuronide conjugates are renally cleared, so LOT drugs are not automatically safe in combined hepato-renal impairment.
• Confusing 'shorter half-lifeThe time it takes for the amount of a drug in the body to fall by half.Read more →' with 'safer metabolism' — the decisive factor is the pathway (oxidation vs conjugation), not half-life alone.

• Identify the drug, receptor, enzyme or pharmacokinetic change named in the stem.
• Translate it into the immediate mechanism before looking at the options.
• Use timing and the adverse-effect pattern to separate the nearest alternatives.
• Check whether the question asks for mechanism, clinical consequence, monitoring or management.